iShares US Healthcare E.T.F.

IYH-N

NYSEARCA:IYH

211.79
0.03 (0.01%)

Analysis and Opinions about IYH-N

Signal
Opinion
Expert
COMMENT
COMMENT
January 25, 2017

He thinks the drivers behind the healthcare sector are as powerful today as they were 6 months ago. However, the environment has been changing, where you need to be more of an active manager, understanding which asset mix makes sense. This is a passive ETF, so you are subject to the whims of the largest names. You should have exposure to the sector, but try to identify something that is more actively managed.

He thinks the drivers behind the healthcare sector are as powerful today as they were 6 months ago. However, the environment has been changing, where you need to be more of an active manager, understanding which asset mix makes sense. This is a passive ETF, so you are subject to the whims of the largest names. You should have exposure to the sector, but try to identify something that is more actively managed.

Dean Orrico
President, Middlefield Capital Corp.
Price
$145.780
Owned
Unknown
PAST TOP PICK
PAST TOP PICK
July 19, 2016

(A Top Pick July 3/15. Down 2.08%.) Sold about 2 months after he had picked it. Didn’t like what was happening in the US elections. Will probably look at getting back into a name like this in November.

(A Top Pick July 3/15. Down 2.08%.) Sold about 2 months after he had picked it. Didn’t like what was happening in the US elections. Will probably look at getting back into a name like this in November.

Mike S. Newton, CIM FCSI
Director & Portfolio Manager, Scotia Wealth Management
Price
$152.860
Owned
No
BUY
BUY
June 8, 2016

As we get closer to the US elections, this is probably a good time to start building a position.

As we get closer to the US elections, this is probably a good time to start building a position.

Mike S. Newton, CIM FCSI
Director & Portfolio Manager, Scotia Wealth Management
Price
$150.520
Owned
No
TOP PICK
TOP PICK
July 3, 2015

A sleeping giant that he has had in his portfolio for a long time. He recommends that you read Byron Wien’s piece about innovation, biotech, healthcare. This ETF has great holdings. 40% exposure to pharmaceuticals, 25% exposure to the biotech sector, a well-rounded portfolio of names. In the past, these names have been thought of as a defensive kind of positioning, but feels they have slowly moved into the growthy areas of the markets, with huge innovations in medical and biotech. In a rising rate environment, if you are looking for something that is defensive but participates with a bit of growth, this might be a really attractive place to hide out.

A sleeping giant that he has had in his portfolio for a long time. He recommends that you read Byron Wien’s piece about innovation, biotech, healthcare. This ETF has great holdings. 40% exposure to pharmaceuticals, 25% exposure to the biotech sector, a well-rounded portfolio of names. In the past, these names have been thought of as a defensive kind of positioning, but feels they have slowly moved into the growthy areas of the markets, with huge innovations in medical and biotech. In a rising rate environment, if you are looking for something that is defensive but participates with a bit of growth, this might be a really attractive place to hide out.

Mike S. Newton, CIM FCSI
Director & Portfolio Manager, Scotia Wealth Management
Price
$159.490
Owned
Yes
COMMENT
COMMENT
June 12, 2015

For the last decade investors have been thinking about healthcare and talking about demographics. For a long time healthcare companies in North America didn’t do much, but that really changed in the last 1.5-2 years. Thinks this is the beginning of a longer-term trend, and we will see continued growth in the healthcare industry. For a long-term proposition, this is not a bad place to be.

For the last decade investors have been thinking about healthcare and talking about demographics. For a long time healthcare companies in North America didn’t do much, but that really changed in the last 1.5-2 years. Thinks this is the beginning of a longer-term trend, and we will see continued growth in the healthcare industry. For a long-term proposition, this is not a bad place to be.

Colin Stewart
CEO & Portfolio manager, JC Clark Investments Ltd.
Price
$158.130
Owned
Unknown
COMMENT
COMMENT
June 11, 2015

Healthcare tends to be a little less correlated to the equity market, so it is an ideal place to be. We are approaching the seasonal strength for biotech at the end of June. The chart on this is showing higher lows and higher highs. A similar one, but hedged to the Cdn$, would be BMO Equal Weight US Healthcare (ZUH-T). (See Top Picks.)

Healthcare tends to be a little less correlated to the equity market, so it is an ideal place to be. We are approaching the seasonal strength for biotech at the end of June. The chart on this is showing higher lows and higher highs. A similar one, but hedged to the Cdn$, would be BMO Equal Weight US Healthcare (ZUH-T). (See Top Picks.)

Jon Vialoux
Research Analyst, CastleMoore Inc.
Price
$159.970
Owned
Unknown
BUY
BUY
November 6, 2013

Owns all the large US healthcare names. Continues to move along at a very nice clip.

Owns all the large US healthcare names. Continues to move along at a very nice clip.

Mike S. Newton, CIM FCSI
Director & Portfolio Manager, Scotia Wealth Management
Price
$110.820
Owned
Yes
BUY
BUY
September 24, 2013

This has big holdings in things like Johnson & Johnson (JNJ-N), Pfizer (PFE-N), Merck (MRK-N), etc. Has done very well year to date.

This has big holdings in things like Johnson & Johnson (JNJ-N), Pfizer (PFE-N), Merck (MRK-N), etc. Has done very well year to date.

Mike S. Newton, CIM FCSI
Director & Portfolio Manager, Scotia Wealth Management
Price
$107.550
Owned
Yes
BUY WEAKNESS
BUY WEAKNESS
April 16, 2007
Likes this area. Going forward, it will be a defensive space. Broke out past its previous resistance point. If you own, Hold. You could add to that on pullbacks.
Likes this area. Going forward, it will be a defensive space. Broke out past its previous resistance point. If you own, Hold. You could add to that on pullbacks.
John Manley
Technical Analyst, Innovative Options Group
Price
$70.680
Owned
Unknown
BUY
BUY
September 28, 2005
Have liked the sector for quite awhile. Has outperformed the S & P 500 since the beginning of the year. Very heavily weighted to large pharma. Short term there's a little bit of a risk, but long term, it's a place you want to have exposure to.
Have liked the sector for quite awhile. Has outperformed the S & P 500 since the beginning of the year. Very heavily weighted to large pharma. Short term there's a little bit of a risk, but long term, it's a place you want to have exposure to.
Larry Berman CFA, CMT, CTA
Chief Investment Officer, Partner, ETF Capital Management Inc.
Price
$61.800
Owned
No
Showing 1 to 10 of 10 entries
  • «
  • 1
  • »